In the current rights issue in NeuroVive, the Board, Senior Executives and employees have undertaken to subscribe for at least 191,200 units equivalent to MSEK 1.5.
The subscription period in the current rights issue in NeuroVive is ongoing until April 24, 2018 and is open to both existing and new investors.
Prospectus, containing full terms and conditions, as well as application forms
are available on NeuroVive's website www.neurovive.com, Stockholm Corporate Finance AB's website www.stockholmcorp.se and Hagberg & Aneborn Fondkommission AB's website www.hagberganeborn.se.
For more information, please contact:
Daniel Schale, Director of Communications
+46 (0)46 275 62 21, email@example.com
NeuroVive Pharmaceutical AB (publ)
Medicon Village, 223 81 Lund, Sweden
Tel: +46 (0)46 275 62 20 (switchboard)
This information is information that NeuroVive Pharmaceutical AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08:30 a.m. CEST on 20 April 2018.
NeuroVive Pharmaceutical AB is a leader in mitochondrial medicine, with one project in clinical phase II development for the prevention of moderate to severe traumatic brain injury (NeuroSTAT®) and one project in clinical phase I (KL1333) for genetic mitochondrial diseases. The R&D portfolio consists of several late stage research programs in areas ranging from genetic mitochondrial disorders to cancer and metabolic diseases such as NASH. The company’s strategy is to advance drugs for rare diseases through clinical development and into the market. The strategy for projects within larger indications outside the core focus area is out-licensing in the preclinical phase. NeuroVive is listed on Nasdaq Stockholm, Sweden (ticker: NVP). The share is also traded on the OTCQX Best Market in the US (OTC: NEVPF).